Financial Disclosure Statement

Kenji Nakayama
Shimadzu Techno-Research (Kyoto Univ. Hospital)

MSACL 2015 EU Abstract Title:
The C-terminal Fragment of Prostate-specific Antigen, a 2331 Da Peptide, as a New Urinary Pathognomonic Biomarker Candidate for Diagnosing Prostate Cancer

Description Y/N Source
Grants no

Salary yes Shimadzu Techno-Research, Inc.

Board Member no

Stock no

Expenses no

IP Royalty: no

Planning to mention or discuss specific products or technology of the company(ies) listed above:
yes

Description	Y/N	Source
Grants	no
Salary	yes	Shimadzu Techno-Research, Inc.
Board Member	no
Stock	no
Expenses	no